The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Axsome Therapeutics Inc shares valued at $2,309,667 were sold by TABUTEAU HERRIOT on Oct 06 ’25. At $120.17 per share, TABUTEAU HERRIOT sold 19,220 shares. The insider’s holdings dropped to 7,229 shares worth approximately $0.89 million following the completion of this transaction.
Also, TABUTEAU HERRIOT sold 13,390 shares, netting a total of over 1,590,330 in proceeds. Following the sale of shares at $118.77 each, the insider now holds 7,229 shares.
Before that, TABUTEAU HERRIOT had sold 12,774 shares from its account. In a trade valued at $1,518,062, the Chief Executive Officer traded Axsome Therapeutics Inc shares for $118.84 each. Upon closing the transaction, the insider’s holdings decreased to 12,774 shares, worth approximately $0.89 million.
As published in their initiating research note from B. Riley Securities on October 01, 2025, Axsome Therapeutics Inc [AXSM] has been a Buy and the price target has been revised to $179. Earlier on June 03, 2025, Oppenheimer initiated its rating. Their recommendation was “an Outperform” for AXSM stock.
Analyzing AXSM Stock Performance
On last trading session, Axsome Therapeutics Inc [NASDAQ: AXSM] rose 3.21% to $122.52. The stock’s lowest price that day was $118.71, but it reached a high of $124.125 in the same session. During the last five days, there has been a surge of approximately 2.15%. Over the course of the year, Axsome Therapeutics Inc shares have jumped approximately 45.58%. Shares of the company reached a 52-week high of $139.13 on 02/21/25 and a 52-week low of $79.19 on 01/10/25.
Support And Resistance Levels for Axsome Therapeutics Inc (AXSM)
According to the 24-hour chart, there is a support level at 119.44, which, if violated, would cause prices to drop to 116.37. In the upper region, resistance lies at 124.86. The next price resistance is at 127.20. RSI (Relative Strength Index) is 58.56 on the 14-day chart, showing neutral technical sentiment.
Is Axsome Therapeutics Inc subject to short interest?
Stocks of Axsome Therapeutics Inc saw a sharp steep in short interest on 2025-09-15 dropping by -0.27 million shares to 3.45 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 3.72 million shares. A decline of -7.8% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.84 of the overall float, the days-to-cover ratio (short ratio) decline to 5.84.
Which companies own the most shares of Axsome Therapeutics Inc (AXSM)?
In terms of Axsome Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 162.5 in the next 12 months, up nearly 36.89% from the previous closing price of $118.71. Analysts anticipate Axsome Therapeutics Inc stock to reach 163 by 2025, with the lowest price target being 162. In spite of this, 15 analysts ranked Axsome Therapeutics Inc stock as Buy at the end of 2025. On April 07, 2025, Jefferies assigned a price target of “a Buy” to the stock and initiated coverage with a $200.
